Preoperative radiation improved T-cell infiltration among patients with hormone receptor-positive, HER2-negative breast ...

In this study, researchers investigated long-term outcomes from a real-world cohort of patients with stage IV melanoma treated with pembrolizumab following progression on prior therapies.

FDA approves pembrolizumab and enfortumab vedotin for neoadjuvant and adjuvant treatment of cisplatin-ineligible muscle-invasive bladder cancer.

Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative ...

Here are 5 notable oncology FDA approvals from last month: ...

Chronic immune-related adverse events occur in more than a third of patients with early-stage TNBC treated with pembrolizumab.

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a ...

Sacituzumab govitecan and pembrolizumab showed a manageable safety profile in PD-L1–positive metastatic TNBC, with lower dose reduction or discontinuation rates than chemotherapy. The combination ...

Under the terms of this agreement, Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the ...

On market launch of the product, Formycon will receive a mid–double-digit-share of gross profits in the region.